Partnership bolsters Boehringer’s autoimmune and inflammatory disease pipeline portfolio aiming to tackle areas of high unmet patient need. The ...

Christian Boehringer to hand over as Chairman of the Shareholders’ Committee to Hubertus von Baumbach Shashank Deshpande, Member of the Board of ...

At the heart of the licensing deal is CUE-501, a bispecific molecule that can selectively deplete B cells to address ...

Boehringer Ingelheim and Cue Biopharma Inc. have joined forces to develop and commercialize Cue Biopharma’s CUE-501 product candidate.

IT can’t sit back - the company’s 2,000 technology professionals must drive the identification of digital solutions to business problems. Line-of-business professionals must also feel comfortable and ...

Cue Biopharma (CUE) stock in focus as the company collaborates with Boehringer Ingelheim to develop CUE-501, for autoimmune ...

Boehringer Ingelheim and Cue Biopharma have entered a strategic research partnership and licence agreement to develop and commercialise the latter’s CUE-501 product candidate for autoimmune conditions ...

Boehringer Ingelheim says it is on track to launch 25 new treatments in its human pharma division onto the market between now and 2030, fuelled by an R&D pipeline that it says is the best in its ...

Boehringer Ingelheim has taken an option on a family of compounds with potential as therapies for schizophrenia from Sosei Heptares, which it says could have broad activity against the symptoms of ...

Boehringer Ingelheim Pharma GmbH & Co KG and Cue Biopharma Inc. have signed a strategic research collaboration and license agreement to develop and commercialize Cue Biopharma’s CUE-501, a ...

GETTING SCHOOLED: President Donald Trump swept into power earlier this year and almost immediately began using his bully pulpit — and the federal government’s leverage, in the form of massive ...